Clene (CLNN) vs Lifevantage (LFVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lifevantage (LFVN) has outperformed Clene (CLNN) over the past year, losing 34.9% versus a loss of 58.8%. Over five years, LFVN leads with a -12.2% price change compared with -96.9% for CLNN. Lifevantage is the larger company by market cap ($75.4 million vs $55.2 million), about 1.4 times the size.
Lifevantage pays a dividend yielding 3.09%, while Clene does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLNN | LFVN |
|---|---|---|
| Share price | $3.88 | $5.99 |
| Market cap | $55.15M | $75.41M |
| 1-day change | -1.02% | -0.17% |
| YTD return | -33.90% | -2.76% |
| 1-year return | -58.81% | -34.89% |
| 5-year return | -96.86% | -12.17% |
| P/E ratio (TTM) | — | 14.97 |
| Forward P/E | — | 15.49 |
| EPS (TTM) | $-3.52 | $0.40 |
| Dividend yield | 0.00% | 3.09% |
| Annual dividend | $0.00 | $0.185 |
| 52-week high | $13.50 | $11.71 |
| 52-week low | $3.25 | $3.90 |
| Distance from 52-week high | -71.26% | -48.85% |
| Analyst consensus | none | none |
| Avg. price target upside | +729.90% | +25.21% |
| Average volume | 100.21K | 59.73K |
| Shares outstanding | 14.21M | 12.59M |
| Employees | 76 | 209 |
| Sector | Consumer Defensive | Consumer Defensive |
| Industry | Packaged Foods | Packaged Foods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LFVN has outperformed CLNN by 23.9 percentage points over the past year.
- Lifevantage offers a meaningfully higher dividend yield (3.09% vs 0.00%).
About Clene
CLNN stock →Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Consumer Defensive · Packaged Foods · 76 employees
About Lifevantage
LFVN stock →LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, gut health, and skin and hair care products in the United States and internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; LifeVantage Daily Wellness, a dietary supplement to strengthen immune health; LifeVantage Rise AM and Reset PM System that provides the body with the right nutrients; LifeVantage D3+, a dietary supplement that provides vitamin D3 and K2, magnesium, calcium, and other trace minerals to support a balanced immune system, strong bones, and cardiovascular health; P84 System, a product activator consisting of PhytoPower 1 and PhytoPower 2 that contains probiotics, prebiotics, postbiotics, digestive enzymes, and superfood blends designed to support gut health; MindBody GLP-1 System, a dietary supplement that combines two products, MB Core and MB Enhance, which are designed to support weight management and wellness by activating GLP-1 naturally and balancing signals along the gut-brain axis; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.
Consumer Defensive · Packaged Foods · 209 employees
CLNN vs LFVN FAQ
Which is bigger, Clene or Lifevantage?
Lifevantage (LFVN) is larger, with a market capitalization of $75.41M compared with $55.15M for Clene (CLNN).
Which stock has performed better over the past year, CLNN or LFVN?
LFVN returned -34.89% over the past 12 months, compared with -58.81% for CLNN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Clene or Lifevantage?
Lifevantage pays a dividend yielding 3.09%, while Clene does not currently pay a regular dividend.
Are Clene and Lifevantage in the same industry?
Yes. Both are classified in the Packaged Foods industry within the Consumer Defensive sector.